Introduction
Constitutive activation of Myc oncogene expression or E2F activity is observed in the majority of human cancers (reviewed in Alitalo et al., 1987; Harbour and Dean, 2000) . c-Myc and E2F-1 are unrelated transcription factors that promote cell growth by regulating the expression of genes that control the G 1 to S phase transition (Eilers et al., 1991; Qin et al., 1994; Shan and Lee, 1994; Mateyak et al., 1997; Santoni-Rugiu et al., 2000) . Overexpression of either c-Myc or E2F-1 can force quiescent cells into S phase in the absence of required mitogens and prevents withdrawal of cells from the cell cycle (Prochownik et al., 1988; Askew et al., 1991; Eilers et al., 1991; Johnson et al., 1993; Qin et al., 1994; Shan and Lee, 1994) ; however, their activities are regulated quite dierently. c-Myc is a basic ± helix ± loop ± helix ± leucine zipper (bHLH-ZIP) protein that mediates both transrepression and transactivation (reviewed in Baudino and Cleveland, 2001) . Transactivation requires interaction with its obligate dimerization partner Max, which is also a bHLH-ZIP protein (Baudino and Cleveland, 2001) . By contrast, E2F-1 and its heterodimeric partner DP-1 transcriptionally activate promoters containing E2F binding sequences (reviewed in Muller and Helin, 2000) . The activity of E2F-1/DP-1 is modulated by association with the retinoblastoma (pRb) tumor suppressor or with the pRb-related proteins p107 and p130, and when E2F-1/ DP-1 is bound to pRb or related proteins these complexes repress transcription (reviewed in Harbour and Dean, 2000) . Therefore, both c-Myc and E2F-1 DNA binding functions are critical for their ability to regulate cell cycle progression (reviewed in Helin, 1998; Grandori et al., 2000) .
In addition to providing continuous proliferative signals, activation of either c-Myc or E2F-1 also triggers apoptosis, particularly when survival factors are limiting (Askew et al., 1991; Evan et al., 1992; Qin et al., 1994; Hiebert et al., 1995; Packham and Cleveland, 1995) . To date, studies in primary murine cells have demonstrated that c-Myc and E2F-1 converge on a common apoptotic pathway involving the p19 ARF and p53 tumor suppressors. The ARFMdm2-p53 pathway is activated by both Myc and E2F-1 (Bates et al., 1998; Zindy et al., 1998) , as well as by other oncoproteins such as Ras and v-Abl (Palmero et al., 1998; Radfar et al., 1998) . Speci®cally, c-Myc and E2F-1 induce the expression of ARF, a product of the alternative reading frame of the INK4a/ARF locus, which leads to p53 stabilization and activates p53-dependent transcription (Bates et al., 1998; Zindy et al., 1998) . This occurs through the ability of ARF to bind and block Mdm2, an inhibitor of p53 (Sherr and Weber, 2000) . Primary cells that lack ARF and/or p53 are more resistant to Mycinduced apoptosis (Hermeking and Eick, 1994; Wagner et al., 1994; Zindy et al., 1998; Eischen et al., 1999) , and similarly, E2F-1-induced apoptosis is impaired in p53-null ®broblasts or cells that express a transdominant mutant of p53 (Qin et al., 1994; Kowalik et al., 1995) . Moreover, in vivo studies have revealed that enforced expression of c-Myc in the B cell compartment of Em-myc transgenic mice synergizes with the loss of ARF or p53 to greatly accelerate lymphoma development (Hsu et al., 1995; Eischen et al., 1999; Jacobs et al., 1999; Schmitt et al., 1999) , and this selection process is associated with marked decreases in Myc-induced apoptosis (Eischen et al., 1999; Jacobs et al., 1999; Schmitt et al., 1999) . Therefore, ARF and p53 play a critical role in Mycand E2F-1-induced apoptosis and tumorigenesis.
A number of reports have suggested that Myc and E2F-1 can also induce apoptosis independent of ARF or p53. Firstly, Myc still induces apoptosis in rat epithelial and ®broblast cells expressing an inactivating p53 mutant or SV40 large T antigen, which blocks p53 function (Sakamuro et al., 1995; Lenahan and Ozer, 1996) . Secondly, although the rate of Myc-induced apoptosis is impaired in p53-and ARF-null primary murine ®broblasts and hematopoietic cells, apoptosis ultimately occurs (Zindy et al., 1998; Eischen et al., 1999) . Finally, p53 accumulation alone is insucient to mediate E2F-1-induced apoptosis in IL-3 dependent 32D.3 murine myeloid cells (Hiebert et al., 1995; Nip et al., 1997) , and human Saos-2 cells that lack p53 still undergo E2F-1-mediated apoptosis (Hsieh et al., 1997; Phillips et al., 1997) . Therefore, targets other than ARF and p53 must also mediate c-Myc-and E2F-1-induced apoptosis.
Anti-apoptotic Bcl-2 family members, such as Bcl-2 and Bcl-X L , inhibit apoptosis initiated by numerous stimuli (reviewed in Korsmeyer, 1999) , including cell death signals induced by Myc and E2F-1 (Bissonnette et al., 1992; Evan et al., 1992; Fanidi et al., 1992; Packham and Cleveland, 1995; Nip et al., 1997; Strom et al., 1998) . Bcl-2 cooperates with Myc in vitro to promote mitogen-independent proliferation and survival (Vaux et al., 1988; Bissonnette et al., 1992; Fanidi et al., 1992) , and accelerates Myc-induced transformation in vivo by blocking apoptosis (Strasser et al., 1990) . Survival factors, such as the cytokines interleukin-3 (IL-3) and Erythropoetin (Epo), selectively regulate the expression of Bcl-X L in primary and immortal myeloid cells (Packham et al., 1998) . A critical threshold appears to exist at which the levels or activity of c-Myc and E2F-1 override the protective eects of survival factors (Qin et al., 1994; Hiebert et al., 1995; Packham and Cleveland, 1995) . For example, increasing the activity of E2F-1 in immortal 32D.3 myeloid cells by co-expressing DP-1 overrides the protective eects of IL-3 and serum and induces apoptosis (Hiebert et al., 1995) . Therefore, the survival of cells also appears to hinge upon changes in the threshold of critical factors regulated by survival signaling pathways.
To de®ne additional mediators of Myc-and E2F-1-induced apoptosis, we used immortal IL-3 dependent murine myeloid cell lines, which are well characterized for their apoptotic response to c-Myc and E2F-1 (Askew et al., 1991; Hiebert et al., 1995; Cleveland, 1995, 1997; Dai et al., 1999) and are defective in the ARF/p53 pathway. We show that overexpression of either c-Myc or E2F-1 selectively suppresses the expression of the apoptotic antagonist Bcl-2 and that this leads to apoptosis. These results support the model whereby oncogenes that augment the apoptotic program selectively target the expression of speci®c Bcl-2 family members.
Results
p53 and ARF are not essential for c-Myc-or E2F-1-induced apoptosis in immortal murine myeloid cells
In some cell contexts p53 is stabilized in response to cMyc (Hermeking and Eick, 1994) or E2F-1 (Nip et al., 2001) and signi®cantly contributes to c-Myc-and E2F-1-induced apoptosis (Qin et al., 1994; Wagner et al., 1994; Zindy et al., 1998; Eischen et al., 1999) . However, in other cell contexts p53 is not required for c-Myc-or E2F-1-induced apoptosis (Melillo et al., 1994; Hermeking et al., 1995; Sakamuro et al., 1995) . 32D.3 immortal myeloid cells are wild-type with respect to p53, and subsequently, express very low levels of p53 ( Figure 1a and see Hiebert et al., 1995) . However, 32D.3 cells that overexpress c-Myc or E2F-1 have increased levels of wild-type p53 protein compared to parental cells ( Figure 1a and Hiebert et al., 1995) . Despite data indicating that Bax is a transcriptional target of Myc in some human tumor cell lines (Mitchell et al., 2000) , immunoblotting for Bax showed equal amounts of protein in each lane (Figure 1a) , and was therefore used as a loading control (Figures 1a, 2c, d, 3a, and 4a) . c-Myc protein is overexpressed approximately ®vefold in c-Myc overexpressing clones (Askew et al., 1991; Packham and Cleveland, 1997) , and the levels of E2F-1 are at least 10-fold greater than endogenous levels of E2F-1 in E2F-1 overexpressing clones (Hiebert et al., 1995) . Therefore Myc and E2F-1 overexpression induces the expression of p53 in 32D.3 cells. However, accumulation of p53 alone does not induce apoptosis, as expression of a temperature sensitive p53 allele (tsp53 135Val), a dominant inhibitor of p53 (Ginsberg et al., 1991) , did not protect E2F-1-expressing cells from etoposide-induced apoptosis (Nip et al., 1997) . To directly address whether p53 mediates E2F-1-induced apoptosis in 32D.3 cells, we analysed stable 32D.3 clones overexpressing tsp53 135Val and E2F-1 and compared them to clones overexpressing E2F-1 or tsp53 135Val alone. At 398C or 378C tsp53 135Val is in a transdominant mutant conformation, whereas at 328C tsp53 135Val is in a wild-type conformation (Ginsberg et al., 1991) . tsp53 135Val protein levels are greater than ®vefold over the levels of wild-type p53 protein in the E2F-1 overexpressing clone, E2F.9 (inset, Figure 1c ), and did not show any dierences in viability in the presence of IL-3, as both clones were greater than 97% viable (time 0, Figure 1c ). Expression of mutant p53 failed to block or delay the accelerated death of E2F-1 overexpressing cells when they were deprived of IL-3 ( Figure 1c ). In fact, the kinetics of cell death following IL-3 withdrawal was similar for all cells overexpressing E2F-1 even when the cells were shifted to 328C (data not shown). Therefore, in 32D.3 cells the acceleration of apoptosis by E2F-1 observed in the absence of IL-3 is independent of p53.
Immortalization and establishment of cells in culture is generally accompanied by loss of p53 function (Askew et al., 1991) were assessed by immunoblotting with antibodies speci®c for each protein. Protein extracts from the indicated mouse embryo ®broblasts (MEFs) were used as controls for p53 and ARF expression. p53 mt is a MEF line having a dominant negative p53 mutation. The sensitivity of a particular clone to accelerated apoptosis following removal of IL-3 is indicated at the bottom of the panels as a plus or minus sign. (b) 32D.3 cells overexpressing E2F-1 (Hiebert et al., 1995) were engineered to express the temperature sensitive Val135 mutant of p53 (tsp53) and were analysed for their levels of Bcl-2 at both permissive (398C, mutant conformation) and restrictive (328C, wild-type conformation) temperatures, relative to E2F-1 overexpressing clones and to control 32D.3 cells overexpressing tsp53. The Neo and Neo plus Hygro vector controls are denoted by N and N/H, respectively. (c) The indicated cells growing in IL-3 were shifted to the permissive (398C) temperature for 24 h and then deprived of IL-3 and kept at this temperature. Cell death was quantitated by trypan blue dye exclusion. Results shown are representative of three separate experiments. Inset, protein levels of p53, wild-type p53 for E2F.9 and tsp53 135Val for E2F.9 tsp53 (Hermeking et al., 1995) or deletion of ARF (Kamijo et al., 1997; Zindy et al., 1998) . In MEFs and primary pre-B cells the tumor suppressor ARF links c-Myc and E2F-1 to p53-mediated apoptosis (Zindy et al., 1998; Eischen et al., 1999) . However, parental 32D.3 cells, or clones overexpressing c-Myc or E2F-1, fail to express ARF RNA or protein ( Figure 1a , data not shown, and see Nip et al., 2001) . Thus, although c-Myc or E2F-1 overexpression leads to increases in p53 levels, ARF is not expressed and therefore the ARF/p53 apoptotic (Packham and Cleveland, 1997) . (c) Levels of Bcl-2 family members in exponentially growing 32D.3 cells overexpressing E2F-1, E2F-1+DP-1, DP-1 or (d) a DNA binding mutant of E2F-1 (E2F-138) were determined by immunoblot with antibodies speci®c for each protein. E2F.1(7) is a control clone which expresses the human E2F-1 cDNA in the antisense orientation (Hiebert et al., 1995) . The sensitivity of a particular clone to accelerated apoptosis following removal of IL-3 (Askew et al., 1991; Hiebert et al., 1995) is indicated at the bottom of the panels as a plus or minus sign pathway is disabled in immortal 32D.3 myeloid cells. Thus, c-Myc and E2F-1 must regulate factors other than ARF and p53 that also participate in the apoptotic response.
c-Myc and E2F-1 selectively suppress Bcl-2 expression in immortal myeloid cells c-Myc or E2F-1 overexpression dramatically accelerates the rates of apoptosis in immortal 32D.3 cells when they are deprived of IL-3 (Askew et al., 1991; Hiebert et al., 1995) , and IL-3 selectively regulates the expression of the Bcl-X L anti-apoptotic protein in these cells (Packham et al., 1998) . We therefore assessed whether signals emanating from c-Myc and E2F-1 in¯uenced the expression of Bcl-X L or other Bcl-2 family proteins in 32D.3 cells, using immunoblot analysis of exponentially growing immortal myeloid cells overexpressing c-Myc or E2F-1. Unexpectedly, in 32D.3 (Figure 2a ) or FDC-P1 (Figure 2b ) cells engineered to overexpress c-Myc, Bcl-2 protein levels were selectively suppressed relative to levels expressed in clones only expressing the Neo vector. By contrast, no signi®cant or consistent changes were observed in any of the other anti-apoptotic (Bcl-X L or Mcl-1) or pro-apoptotic (Bax, Bad, or Bak) Bcl-2 family members analysed (Figure 2 and data not shown). Bcl-2 levels were also selectively suppressed in 32D.3 cells programmed to overexpress E2F-1 or both E2F-1 and DP-1 (Figures 1b and 2c) . By contrast, levels of Bcl-2 remained unchanged in 32D.3 cells engineered to overexpress only DP-1, which do not display accelerated apoptosis when deprived of IL-3 (Hiebert et al., 1995) , relative to Neo-only expressing clones ( Figure  2c ). Again, in 32D.3 myeloid cells E2F-1-induced suppression of Bcl-2 was selective, without appreciable eects on other Bcl-2 family members.
To determine whether c-Myc and E2F-1 transcription functions were required for Bcl-2 suppression, 32D.3 and FDC-P1 cell lines expressing mutants of Myc (Myc-In373) and E2F-1 (E2F-138) that cannot bind DNA were established (Hiebert et al., 1995; Packham and Cleveland, 1997) . In FDC-P1 cells overexpression of Myc-In373 did not suppress Bcl-2 levels, whereas Bcl-2 was reduced by overexpressing wild-type c-Myc (Figure 2b) . Similarly, in 32D.3 cells overexpression of E2F-138 did not result in reductions of Bcl-2 (Figure 2d ). In addition, unlike cells overexpressing wild-type c-Myc and E2F-1 proteins, cells overexpressing Myc-In373 or E2F-138 did not display an acceleration of apoptosis when they were deprived of IL-3 (Packham and Cleveland, 1997; Nip et al., 2001) . Since p53 does not mediate E2F-1-induced apoptosis in 32D.3 cells (Figure 1c) , we predicted that it would not be required for E2F-1-induced Bcl-2 suppression. As expected, cells that overexpressed E2F-1 and tsp53 had reduced levels of Bcl-2 independent of whether p53 was in its wild-type (328C) or mutant (398C) conformation (Figure 1b) . Thus, overexpression of c-Myc or E2F-1 sensitizes cells to apoptosis by selectively suppressing the apoptotic antagonist Bcl-2, 
Bcl-2 rescues cells that overexpress c-Myc or E2F-1 from apoptosis
If Bcl-2 suppression by c-Myc or E2F-1 was relevant to oncogene-mediated cell death, reconstitution of Bcl-2 levels should protect cells that overexpress c-Myc and E2F-1 from apoptosis. To address this issue, we co-transfected parental 32D.3 cells and clones overexpressing c-Myc or E2F-1 with expression vectors harboring human bcl-2 and/or the hygromycin B resistance gene and selected clonal cell lines. Bcl-2 levels in exponentially growing, antibiotic-resistant pools and clones were assessed by immunoblot, and clones were identi®ed that re-constituted Bcl-2 levels similar to those observed in vector-only control 32D.3 cells (Figure 3a) . Bcl-2 reconstitution to levels present in 32D.3 cells eectively abolished the accelerated rates of apoptosis of c-Myc overexpressing cells following IL-3 withdrawal, and supra-physiological levels of Bcl-2 blocked E2F-1-induced cell death (Figure 3b,c) . Cell death was also blocked by Bcl-2 overexpression in parental 32D.3 cells deprived of IL-3 (Figure 3b ). Therefore the suppression of Bcl-2 by cMyc or E2F-1 is relevant to their ability to augment this cell death program.
Finally, to address whether the suppression of Bcl-2 was speci®c to E2F-1 overexpression and not to genetic alterations caused by E2F-1 overexpression, we isolated an antibiotic-resistant revertant of an E2F-1 clone (E2F.9-R). This revertant had diminished levels of E2F-1 expression and had Bcl-2 levels comparable to those present in parental 32D.3 cells (Figure 4a) . Furthermore, the revertant, when deprived of IL-3, lost the accelerated death phenotype seen in parental E2F-1 overexpressing cells (Figure 4b ). Although other alternatives could account for the reduced levels of E2F-1 and apoptosis in this clone, the increased levels of Bcl-2 in these cells suggests that the two are linked.
Myc and E2F-1 suppress Bcl-2 RNA expression
Suppression of Bcl-2 levels in myeloid cells overexpressing c-Myc or E2F-1 could be due to alterations in the stability of Bcl-2 protein, or the expression of bcl-2 RNA. To test whether Bcl-2 protein half-life was reduced in cells that overexpressed c-Myc or E2F-1 as compared to Neo controls, pulse-chase experiments were performed. The overall levels of Bcl-2 protein detected in pulse-labeled cells were markedly diminished in cells overexpressing c-Myc or E2F-1 relative to 32D.3 cells expressing Neo alone ( Figure 5) . However, the half-life of Bcl-2 protein was comparable in all cells (approximately 12 h, Figure 5 ). The reductions in Bcl-2 protein in pulse-labeled cMyc or E2F-1 overexpressing cells suggested that this could be due to a reduction in bcl-2 transcripts. Indeed, Northern blot analysis revealed that the steady state levels of bcl-2 RNA were greatly diminished in clones overexpressing c-Myc (Figure 6a ) or E2F-1 ( Figure  6b ). By contrast, the expression of other Bcl-2 family members were not consistently altered, including those of bax (Figures 6a,b) , which has been suggested as a cMyc gene target (Mitchell et al., 2000) . Therefore, the reductions in Bcl-2 protein in immortal myeloid cells engineered to overexpress c-Myc or E2F-1 are due to the suppression of bcl-2 RNA levels. Thus, c-Myc and E2F-1 suppress Bcl-2 expression at a transcriptional or post-transcriptional level.
Discussion
c-Myc and E2F-1 are activated in most tumors, yet in¯uence both cell growth and cell death (Askew et al., 1991; Eilers et al., 1991; Evan et al., 1992; Qin et al., 1994; Shan and Lee, 1994; Mateyak et al., 1997; Santoni-Rugiu et al., 2000) . The proper expression and levels of c-Myc or E2F-1 are required to allow S phase entry (Eilers et al., 1991; Qin et al., 1994; Shan and Lee, 1994; Mateyak et al., 1997; Santoni-Rugiu et al., 2000) , whereas inappropriate expression or elevated levels of either oncoprotein induce apoptosis (Askew et al., 1991; Evan et al., 1992; Hiebert et al., 1995) , and this is an eective mechanism to suppress tumorigenesis. Thus, if pathways that mediate Myc-or E2F-1-induced apoptosis are disabled, then the oncoproteins can function as strict growth promoters (Eischen et al., 1999; Schmitt et al., 1999) . Indeed, overexpression of Myc or E2F-1 activates the ARFMdm2-p53 pathway, which elicits an apoptotic response (Zindy et al., 1998; Eischen et al., 1999; Schmitt et al., 1999) . However, we and others have shown that c-Myc-and E2F-1-induced apoptosis can occur independent of ARF and/or p53 in both immortal and primary cells (Melillo et al., 1994; Sakamuro et al., 1995; Eischen et al., 2001) . Utilizing immortal myeloid cells that lack a functional ARF/ p53 pathway we report the identi®cation of a second essential pathway shared by c-Myc and E2F-1 that leads to cell death. Speci®cally, our ®ndings support the concept that in immortal myeloid cells c-Myc and E2F-1 induce apoptosis by selectively suppressing Bcl-2 expression.
Myc and E2F-1 sensitize cells to apoptosis induced by numerous stimuli, including cytokine deprivation, chemotherapeutics, DNA damage, hypoxia, heat shock, TNF-a, and antigen receptor activation (reviewed in Prendergast, 1999) . Our data supports this concept and provides an explanation for this generalized response. The c-Myc-and E2F-1-induced decreases in Bcl-2 levels occurs selectively without aecting the expression of other Bcl-2 family members. This scenario would render cells more susceptible to apoptosis by altering the balance between anti-and pro-apoptotic Bcl-2 family members in favor of those members that induce cell death. Bcl-2 and other antiapoptotic Bcl-2 family members inhibit the mitochondrial release of cytochrome c from mitochondria, thereby blocking the activation of Apaf-1 and the sequential activation of caspase-9 and caspase-3, resulting in cell survival (reviewed in Gross et al., 1999) . The suppression of Bcl-2 expression by c-Myc and E2F-1 is also consistent with the observation that c-Myc activation triggers the p53-independent release of cytochrome c and apoptosis in ®broblasts, which is blocked by Bcl-2 overexpression (Juin et al., 1999) . Therefore, the decrease in Bcl-2 explains why oncogenes such as c-Myc and E2F-1 sensitize cells to a variety of apoptotic insults.
Although the use of cell lines to uncover apoptotic regulators is arguably risky, particularly in regards to the ARF/p53 pathway, these studies have revealed a critical apoptotic pathway that is also active under more physiological conditions. Speci®cally, analysis of primary myeloid CD34 + stem cells revealed that Myc activation results in a decrease in Bcl-X L expression , whereas the present study shows that Bcl-2 levels are suppressed by Myc in more mature immortal CD34 7 myeloid cell precursors. We believe that these selective context-speci®c eects are a result of the dierence in the stage of dierentiation between the two myeloid cell populations rather than a result of immortalization, and several lines of evidence support . Secondly, Bcl-X L and Bcl-2 expression is developmentally regulated. Bcl-X L is high in precursor lymphocytes and low in mature cells, whereas Bcl-2 expression is high in mature lymphocytes and low in immature cells (Merino et al., 1994; Grillot et al., 1996) . Finally, Bcl-X L appears essential for de®nitive hematopoiesis during embryogenesis (Motoyama et al., 1995) . By contrast, deletion of Bcl-2 compromises the survival of mature lymphocytes (Veis et al., 1993; Nakayama et al., 1994) . These ®ndings support the concept that Bcl-X L is critical for hematopoietic cell maturation, whereas Bcl-2 is essential for survival of more mature hematopoietic cells. Our results are consistent with this notion and suggest that Myc and E2F-1 suppress the expression of the particular Bcl-2 family member that is most important for the survival of that speci®c cell type. Alternatively, Myc and E2F-1 may down-regulate Bcl-2 or Bcl-X L to aid in cell cycle progression, as Bcl-2 can inhibit cell cycle progression by extending the G1 phase of the cell cycle (Huang et al., 1997; O'Connor et al., 2000) .
Myc and E2F-1 function as transcription factors that regulate genes essential for progression through G1 and early S phase (Eilers et al., 1991; Qin et al., 1994; Shan and Lee, 1994; Mateyak et al., 1997; SantoniRugiu et al., 2000) . Although the DNA binding functions of c-Myc and E2F-1 are essential for the suppression of Bcl-2 and the induction of apoptosis in immortal myeloid cells, it is unclear whether c-Myc or E2F-1 transactivation or transrepression functions are required for this eect. Utilizing mutants of c-Myc or E2F-1 that bind DNA but are unable to transactivate, others have shown that transactivation is dispensible for Myc-and E2F-1-induced apoptosis (Hsieh et al., 1997; Phillips et al., 1997; Conzen et al., 2000; Nesbit et al., 2000) . In addition, expression of Myc-S (short), a protein lacking the ®rst 100 amino acids and defective in transactivation, is still able to induce apoptosis (Xiao et al., 1998) . On the other hand, cMyc's transrepression functions appear necessary for cMyc-induced apoptosis (Conzen et al., 2000) and transformation (Lee et al., 1996) .
Several observations suggest that both c-Myc-and E2F-1-mediated suppression of bcl-2 gene expression is indirect, although the means by which each accomplishes this may be dierent. Firstly, most genes repressed by Myc contain a pyrimidine-rich cis-initiator (Inr) element (Roy et al., 1993; Li et al., 1994) , and the bcl-2 gene appears to lack an initiator; however, Myc could repress bcl-2 by an Inr-independent mechanism. Secondly, Figure 6 Myc and E2F-1 overexpression suppresses bcl-2 RNA levels. Total RNA was prepared from exponentially growing 32D cells or clones overexpressing Myc (a) or E2F-1 (b) and analysed for levels of bcl-2, bcl-X and bax transcripts. E2F(7).1 is a control clone which expresses the human E2F-1 cDNA in the antisense orientation (Hiebert et al., 1995) . Probing of b-actin was done to equalize loading of RNA. The sensitivity of a particular clone to accelerated apoptosis following removal of IL-3 is indicated at the bottom of the panels as a plus or minus sign alleviation of E2F-1-dependent transrepression appears to enhance E2F-1-induced apoptosis (Phillips et al., 1997) . Therefore, although Myc may require transrepression to induce apoptosis, E2F-1 appears to act via derepression. Thirdly, using the inducible Myc-ER TM system (Littlewood et al., 1995) , we have shown that cycloheximide treatment abrogates Myc's ability to suppress bcl-X expression in pre-B cells ; therefore, suppression of bcl-X expression by Myc is indirect and requires new protein synthesis. Unfortunately, we have been unable to use this system in the immortal cell lines used in this study as expression of Myc-ER TM , which is somewhat leaky in some cell systems (Zindy et al., 1998; Eischen et al., 1999) , is toxic. Finally, overexpression of a downstream transcription target of c-Myc, ornithine decarboxylase (ODC), also suppresses Bcl-2 RNA and protein expression in 32D.3 cells (JL Cleveland, unpublished results) and induces apoptosis (Packham and Cleveland, 1994) . However, ODC overexpression has no eect on c-Myc levels or E2F activity (JL Cleveland, unpublished results). Overall these ®ndings suggest that the suppression of Bcl-2 by cMyc or E2F-1 is indirect, yet is likely to be mediated by a transcriptional response.
Our results suggest that Bcl-2 is a common and selective target for suppression by oncoproteins that activate apoptosis in myeloid cells. In addition to c-Myc and E2F-1, c-Myb and Pim-1 regulate bcl-2 transcription, whereas the tumor suppressors p53 and p16 INK4a suppress bcl-2 expression (Miyashita et al., 1994; Frampton et al., 1996; Taylor et al., 1996; Lilly et al., 1999; Kataoka et al., 2000) . Therefore, it is not surprising that most cancers have lost p53 or Ink4a/ARF function (reviewed in Sherr and Weber, 2000) . Moreover, the upregulation of Bcl-2 or Bcl-X L is observed in many human cancers (Reed et al., 1996) . This indicates that both p53 and Bcl-2 pathways are targeted in cancer. Bcl-2 overexpression provides a survival signal, while inactivation of ARF/Ink4a or p53 relieves constraints on cell proliferation and further impairs the capacity to induce apoptosis. Interestingly, ARF/Ink4a is deleted or p53 is mutated in half of the pre-B and B cell lymphomas arising in Em-myc transgenic mice (Eischen et al., 1999) . In addition, we have recently determined that Bcl-2 and/ or Bcl-X L are overexpressed in the majority of lymphomas irrespective of ARF or p53 status . Therefore, it will be critical to determine the identity of the eectors involved in c-Myc-and E2F-1-induced Bcl-2 suppression, to determine how this pathway is corrupted in cancer, and whether these targets would serve as practical therapeutic targets.
Materials and methods

Cell lines and clones
IL-3-dependent immortal 32D.3 and FDCP-1 myeloid cells, and clones of these cells engineered to overexpress c-Myc, Myc-In373, E2F-1, E2F-1+DP-1, DP-1, E2F-138 or Neoonly have been previously described (Askew et al., 1991; Hiebert et al., 1995; Cleveland, 1995, 1997; Nip et al., 2001) . All immortal myeloid cells and clones were grown in RPMI 1640 containing 10% FBS and 20 units IL-3/ml (growth medium). c-Myc, Myc-In373, E2F-1, DP-1, E2F-138, and Neo-only expressing cells were grown in growth medium containing G418; E2F-1+DP-1 expressing clones were grown in growth medium containing G418 plus hygromycin B. Clones of parental 32D.3 cells or 32D.3 cells overexpressing c-Myc or E2F-1 and also expressing human Bcl-2 were generated by co-electroportion of the pSFFV Bcl-2 expression vector (kindly provided by S Korsmeyer) with an expression vector (pRMM) harboring the hygromycin B resistance gene, and individual clones were generated from hygromycin-resistant pools by limiting dilution. The generation of 32D.3 and E2F-1 overexpressing 32D.3 cells expressing the temperature sensitive p53 (tsp53 135Val, (Ginsberg et al., 1991) was previously described (Nip et al., 1997) .
Viability and apoptosis assays
To assure that cells analysed were at a similar exponential growth phase to allow comparisons of protein levels and rates of cytokine deprivation-induced apoptosis, the 32D.3 and FDCP-1 cells and clones were split on two consecutive days at 5610 5 cells/ml, and on the third day they were analysed for protein levels (Askew et al., 1991) . Cell viability was determined at speci®c intervals by trypan blue dye exclusion following IL-3 deprivation. Cells expressing the tsp53 were grown at 398C, where p53 is in the transdominant mutant conformation, and then shifted to 328C, where tsp53 is in the wild-type conformation (Ginsberg et al., 1991) . Apoptosis was con®rmed morphologically by visual examination of Wright-Giemsa stained cytospins, and other assays of apoptosis using these cell systems con®rmed that these cell deaths are apoptotic (Askew et al., 1991; Dai et al., 1999) .
Pulse chase analysis
Cells were radiolabeled with 35 S-methionine in medium lacking methionine for 2 h, washed in medium containing 106cold methionine twice, and either lysed and immunoprecipitated with anti-murine Bcl-2 (15021, PharMingen, San Diego, CA, USA) or incubated for the indicated intervals before lysis and immunoprecipitation. Immunoprecipitates were resolved on 12% polyacrylamide gels containing sodium dodecyl sulfate (SDS) and processed for autoradiography. Decay of Bcl-2 signal was measured using densitometry.
Northern and Western blotting
Total RNA isolation and Northern blotting were performed using conventional techniques. For Northern blots the coding portions of murine bcl-2, bcl-X, and bax cDNAs were used (kindly provided by Drs D Askew, C Thompson, and J Reed, respectively). Membranes were probed with the coding portion of b-actin to equalize loading of RNA. For Western blotting, whole cell protein extracts from 32D.3 or FDC-P1 cells were isolated as previously described (Packham et al., 1998; Eischen et al., 1999) . Equal amounts of protein per lane (50 ± 125 mg/lane) was electrophoretically separated in 7.5% or 10% SDS polyacrylamide gels. Lysates from mouse embryo ®bro-blasts (MEFs) were previously described (Zindy et al., 1998) and run as controls. Proteins were transferred to nitrocellulose membranes (Protran, Schleicher and Schuell, Dassel, Germany) and blotted with antibodies speci®c for p53 (AB-7, Calbiochem, La Jolla, CA, USA), p19 ARF (Quelle et al., 1995) , murine c-Myc (06-340, Upstate Biotechnology, NY, USA), E2F-1 (Kato et al., 1993) , Bcl-2 (15021, PharMingen, San Diego, CA, USA), Bcl-X L (B2260, Transduction Labs, San Diego, CA, USA), Bax (13686E, PharMingen), and Bak (Upstate Biotechnology, NY, USA). Bound immunocomplexes were detected by enhanced chemiluminescence (Amersham) or Supersignal (Pierce, Rockford, IL, USA).
